Clomifene Citrate
Phase 3Small molecule
Clomifene Citrate is one of 35 small molecule programs targeting Ovarian. It is currently in Phase 3.
3
Indications
5
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
23 competitors in Ovarian Reserve
#DrugCompanyPhaseTrials
1Myoinositol
SSohag University
Phase 3
Clomifene Citrate
UUniversity of Nottingham
Phase 3
Co-Enzyme Q10
TTanta University
Phase 3
Remicade
Johnson & JohnsonPreclinical
Thalomid
Bristol-Myers SquibbPreclinical
Trexall
Jazz PharmaceuticalsPreclinical
Danocrine
SanofiPreclinical
Zoladex
TTerSera Therapeutics LLC
Preclinical
Growth Hormone
PfizerPreclinical
Recombinant LH
UUniversity of Colorado, Denver
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Azoospermia1 trial
CLE1 trial
Ovarian Reserve1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Clomifene Citrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Nottingham